CSIMarket Company Name, Ticker, Competitors, else..
 
Disc Medicine Inc   (NASDAQ: IRON)
Other Ticker:  
 
 
Price: $41.3100 $1.04 2.583%
Day's High: $41.41 Week Perf: 6.74 %
Day's Low: $ 39.54 30 Day Perf: -19.43 %
Volume (M): 424 52 Wk High: $ 68.73
Volume (M$): $ 17,532 52 Wk Avg: $49.02
Open: $40.03 52 Wk Low: $25.64



 Market Capitalization (Millions $) 1,141
 Shares Outstanding (Millions) 28
 Employees 60
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -109
 Cash Flow (TTM) (Millions $) -168
 Capital Exp. (TTM) (Millions $) 1

Disc Medicine Inc
Disc Medicine Inc. is a biotechnology company that focuses on developing novel therapeutic treatments for patients with serious and debilitating diseases related to red blood cell disorders. The company specializes in finding innovative solutions for disorders that involve the dysregulation of iron metabolism, such as iron-refractory iron deficiency anemia (IRIDA) and beta-thalassemia. By utilizing cutting-edge research and technologies, Disc Medicine aims to provide breakthrough therapies that can significantly improve the quality of life for patients suffering from these conditions.


   Company Address: 321 Arsenal Street, Suite 101 Watertown 2472 MA
   Company Phone Number: 674-9274   Stock Exchange / Ticker: NASDAQ IRON


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY   -2.92%    
JNJ        3.78% 
LLY        14.68% 
MRK   -1.49%    
SNY   -1.19%    
TEVA        3.82% 
• View Complete Report
   



Product Service News

Strategic Advancements in Hematologic Treatment Disc Medicines Positive FDA Engagement and Financial Adjustment in t...

Published Tue, Jan 21 2025 12:58 PM UTC

Abstract: Disc Medicine, Inc., a pioneering clinical-stage biopharmaceutical firm, has recently reported encouraging outcomes from its Type C meeting with the U.S. Food and Drug Administration (FDA) regarding the APOLLO post-marketing confirmatory trial for bitopertin, targeting erythropoietic protoporphyria (EPP). Alongside the regulatory progress, a retrospective examina...
Financing Agreement

Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc. to Propel Clinical Advancements in Hematology.,

Published Fri, Nov 8 2024 1:30 PM UTC

Disc Medicine Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company specializing in treatments for serious hematologic diseases, has recently announced a significant financial milestone that positions the company for sustained growth and innovation in the field. The company secured a $200 million non-dilutive term loan facility from Hercules Capital, Inc. (NYSE:HTGC...
Clinical Study

Disc Medicine Reveals Promising Clinical Advances Ahead of ASH Annual Meeting A Gamechanger in Hematology,

Published Tue, Nov 5 2024 2:00 PM UTC

Emerging Innovations in Hematologic Disease Treatment: A Spotlight on Disc Medicine Disc Medicine, Inc., a clinical-stage biopharmaceutical company operating in the niche of hematologic diseases, is making significant strides in both research and clinical development. As they prepare for their presentations at the 66th American Society of Hematology (ASH) Annual Meeting sc...
Clinical Study

Promising New Data for DISC-0974 at ASN Kidney Week A Potential Game Changer for Chronic Kidney Disease and Anemia

Published Fri, Oct 11 2024 12:00 PM UTC

Disc Medicine, Inc., a clinical-stage biopharmaceutical company, recently announced to present new clinical data from its ongoing Phase 1b trial of DISC-0974 at the 2024 American Society of Nephrology (ASN) Kidney Week. The trial focuses on patients with non-dialysis dependent chronic kidney disease (NDD CKD) and anemia a population that has been significantly underserved...
Financing Agreement

Disc Medicine Raises $178 Million through Successful Underwritten Offering of Common Stock

Published Fri, Jun 14 2024 12:04 PM UTC



In a significant move towards advancing its mission of revolutionizing the treatment landscape for serious hematologic diseases, Disc Medicine, Inc., a prominent clinical-stage biopharmaceutical company, has announced the pricing of an underwritten offering of its common stock. This offering paves the way for the company to generate approximately $178.0 million in ...









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com